



Championing a Smoke-Free World

Matthew R. Holman, Ph.D. Vice President & Chief Science & Regulatory Strategy Officer, U.S^(a)

September 28, 2023

(a) Office of Science Director at FDA's Center for Tobacco Products (2017-2022)

Forward-Looking and Cautionary Statements

- This presentation contains projections of future results and goals and other forward-looking statements, including statements regarding business and
 regulatory plans, expectations, opportunities, ambitions, targets, and strategies. These forward-looking statements and anticipated results reflect the
 current views and assumptions of management and are inherently subject to significant risks, uncertainties and inaccurate assumptions. In the event that
 risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forwardlooking statements. Pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors
 that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking
 statements made by PMI
- PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchase; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected
- PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth
 quarter and year ended December 31, 2022 and Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023. PMI cautions that the
 foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forwardlooking statement that it may make from time to time, except in the normal course of its public disclosure obligations

Glossary and Key Terms and Definitions

- A glossary of terms, including the definition for smoke-free products as well as adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures for non-GAAP financial measures cited in this presentation are available on our <u>Investor Relations website</u>
- Growth rates presented on an organic basis reflect currency-neutral adjusted results, excluding acquisitions and disposals. As such, figures and comparisons presented on an organic basis exclude Swedish Match up until November 11, 2023

Heated Tobacco Products Applications

- IQOS 3.0 MRTPA renewal submitted in July:
 - Blade technology
 - Tobacco & menthol flavors
 - MRTPA claim: 'complete switching from smoking leads to significant decrease in toxicant exposure'
 - MRTPA renewal due in July 2024
- IQOS ILUMA PMTAs/MRTPAs submission planned in Q4:
 - Induction technology
 - Tobacco & menthol flavors
 - Same reduced exposure claims as IQOS 3.0



Swedish Snus - First MRTP Authorized by FDA



- General Snus MRTPA renewal submitted in July:
 - Tobacco, mint, & wintergreen flavors
 - MRTPA claim: "Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
 - -MRTPA renewal due in Oct 2024


Nicotine Pouch Applications

- ZYN PMTAs submitted in March 2020 :
 - Dry pouches
 - 2 strengths
 - 10 flavors
 - Marketed under enforcement discretion
- ZYN Ultra PMTAs submitted in Nov 2021:
 - Moist pouches
 - 2 strengths
 - 10 flavors
 - Not marketed



5





Overcoming Regulatory Challenges

- Substantial PMTA backlog:
 - Long queue
 - Unpredictable timing
- PMI is developing innovative products:
 - Example: IQOS ILUMA converts more smokers than IQOS 3.0
- Confident of success with authorizations:
 - Submitting robust data on 'appropriate for protection of public health'
 - Hired regulatory science experts who can engage
 - FDA aims to better educate adult smokers







Championing a Smoke-Free World

Have you downloaded the new PMI Investor Relations App yet?

The free IR App is available to download at the Apple App Store for iOS devices and at Google Play for Android mobile devices





Android Download